Advances in lung transplantation for interstitial lung diseases.
Adrenal Cortex Hormones
Anti-Inflammatory Agents, Non-Steroidal
/ therapeutic use
Extracorporeal Membrane Oxygenation
Humans
Indoles
/ therapeutic use
Lung Diseases, Interstitial
/ surgery
Lung Transplantation
Nutritional Status
Patient Selection
Perioperative Care
Preoperative Care
Protein Kinase Inhibitors
/ therapeutic use
Pyridones
/ therapeutic use
Journal
Current opinion in pulmonary medicine
ISSN: 1531-6971
Titre abrégé: Curr Opin Pulm Med
Pays: United States
ID NLM: 9503765
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
24
7
2020
medline:
25
6
2021
entrez:
24
7
2020
Statut:
ppublish
Résumé
Lung transplantation (LTx) is increasingly used as ultimate treatment modality in end-stage interstitial lung diseases (ILDs). This review aims to give an overview of the latest evolutions in this field. In the last two years, important new findings regarding LTx outcomes in specific ILD entities have been reported. More data are available on optimization of pre-LTx management of ILD patients especially with regard to pretransplant antifibrotic treatment. LTx is the only treatment option with curative intent for ILDs and is increasingly used for this indication. Several studies have now reported adequate outcomes in different ILD entities, although outcome is shown to be affected by underlying telomeropathies. As new studies could not replicate inferior survival with single compared with double LTx, both options remain acceptable. ILD specialists can beneficially impact on post-LTx outcome by optimizing pre-LTx management: corticosteroids should be avoided, antifibrotics should be initiated whenever possible and BMI and nutritional status optimized, rehabilitation and depression-screening strategies should be implemented in all LTx candidates, as these interventions may all improve postlung transplant survival.
Identifiants
pubmed: 32701669
doi: 10.1097/MCP.0000000000000690
pii: 00063198-202009000-00020
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Anti-Inflammatory Agents, Non-Steroidal
0
Indoles
0
Protein Kinase Inhibitors
0
Pyridones
0
pirfenidone
D7NLD2JX7U
nintedanib
G6HRD2P839
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
518-525Références
Dempsey TM, Sangaralingham LR, Yao X, et al. Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2019; 200:168–174.
Salisbury ML, Gu T, Murray S, et al. Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory. Chest 2019; 155:699–711.
Chambers DC, Cherikh WS, Harhay MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart–lung transplantation Report—2019; focus theme: donor and recipient size match. J Hear Lung Transplant 2019; 38:1042–1055.
Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014 – an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Hear Lung Transplant 2015; 34:1–15.
Russo MJ, Worku B, Iribarne A, et al. Does lung allocation score maximize survival benefit from lung transplantation? J Thorac Cardiovasc Surg 2011; 141:1270–1277.
Dotan Y, Vaidy A, Shapiro WB, et al. Effect of acute exacerbation of idiopathic pulmonary fibrosis on lung transplantation outcome. Chest 2018; 154:818–826.
Hayanga JW, Hayanga HK, Holmes SD, et al. Mechanical ventilation and extracorporeal membrane oxygenation as a bridge to lung transplantation: closing the gap. J Hear Lung Transplant 2019; 38:1104–1111.
Hayanga JW, Hayanga HK, Fugett JH, et al. Contemporary look at extracorporeal membrane oxygenation as a bridge to reoperative lung transplantation in the United States: a retrospective study. Transpl Int 2020; doi:10.1111/tri.13617 [Epub ahead of print].
doi: 10.1111/tri.13617
Ko RE, Lee JG, Kim SY, et al. Extracorporeal membrane oxygenation as a bridge to lung transplantation: Analysis of Korean organ transplantation registry (KOTRY) data. Respir Res 2020; 21:1–8.
Hayanga AJ, Aboagye J, Esper S, et al. Extracorporeal membrane oxygenation as a bridge to lung transplantation in the United States: an evolving strategy in the management of rapidly advancing pulmonary disease. J Thorac Cardiovasc Surg 2015; 149:291–296.
Benazzo A, Schwarz S, Frommlet F, et al. Twenty-year experience with extracorporeal life support as bridge to lung transplantation. J Thorac Cardiovasc Surg 2019; 157:2515–2525.e10.
Biscotti M, Gannon WD, Agerstrand C, et al. Awake extracorporeal membrane oxygenation as bridge to lung transplantation: a 9-year experience. Ann Thorac Surg 2017; 104:412–419.
Nathan SD, Shlobin OA, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008; 76:288–294.
Nowak J, Hudzik B, Przybyłowski P, et al. Prognostic value of mean, diastolic, and systolic pulmonary artery pressure in patients with end-stage lung disease referred for lung transplantation. Transplant Proc 2018; 50:2048–2052.
Corral-Blanco M, Prudencio-Ribera VC, Jarrín-Estupiñán ME, et al. Influence of pulmonary hypertension on intrahospital mortality in lung transplantation for interstitial lung disease. Transplant Proc 2019; 51:380–382.
Prudencio-Ribera VC, Corral-Blanco M, Jarrín-Estupiñán ME, et al. Analysis of intrahospital mortality in patients with lung transplant due to diffuse parenchymal lung disease. Transplant Proc 2019; 51:372–375.
Cottini SR, Brandi G, Pagnamenta A, et al. Pulmonary hypertension is not a risk factor for grade 3 primary graft dysfunction after lung transplantation. Clin Transplant 2018; 32:1–6.
Chicotka S, Pedroso FE, Agerstrand CL, et al. Increasing opportunity for lung transplant in interstitial lung disease with pulmonary hypertension. Ann Thorac Surg 2018; 106:1812–1819.
Valapour M, Lehr CJ, Skeans MA, et al. OPTN/SRTR 2018 annual data report: lung. Am J Transplant 2020; 20:427–508.
Young KA, Dilling DF. The future of lung transplantation. Chest 2019; 155:465–473.
Somers J, Ruttens D, Verleden SE, et al. A decade of extended-criteria lung donors in a single center: was it justified? Transpl Int 2015; 28:170–179.
Woolley AE, Singh SK, Goldberg HJ, et al. Heart and lung transplants from HCV infected donors to uninfected recipients. N Engl J Med 2019; 380:1606–1617.
Grewal HS, Highland KB, McCurry K, et al. Bacterial meningitis as a cause of death in lung transplant donors: early outcomes in recipients. Clin Transplant 2018; 32:1–5.
Sugimoto S, Kurosaki T, Otani S, et al. Feasibility of lung transplantation from donors mechanically ventilated for prolonged periods. Surg Today 2019; 49:254–260.
Charles EJ, Huerter ME, Wagner CE, et al. Donation after circulatory death lungs transplantable up to six hours after ex vivo lung perfusion. Ann Thorac Surg 2016; 102:1845–1853.
Van Raemdonck D, Keshavjee S, Levvey B, et al. Donation after circulatory death in lung transplantation: five-year follow-up from ISHLT registry. J Hear Lung Transplant 2019; 38:1235–1245.
Cypel M, Yeung JC, Mingyao L, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364:1431–1440.
Warnecke G, Van Raemdonck D, Smith MA, et al. Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, noninferiority, phase 3 study. Lancet Respir Med 2018; 6:357–367.
Schaffer JM, Singh SK, Reitz BA, et al. Single-vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. JAMA 2015; 313:936–948.
Panchabhai TS, Arrossi AV, Patil PD, et al. Unexpected neoplasms in lungs explanted from lung transplant recipients: a single-center experience and review of literature. Transplant Proc 2018; 50:234–240.
Raviv Y, Shitrit D, Amital A, et al. Lung cancer in lung transplant recipients: experience of a tertiary hospital and literature review. Lung Cancer 2011; 74:280–283.
Chauhan D, Karanam AB, Merlo A, et al. Posttransplant survival in idiopathic pulmonary fibrosis patients concurrently listed for single and double lung transplantation. J Hear Lung Transplant 2016; 35:657–660.
Spratt JR, Tomic R, Brown RZ, et al. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis in the lung allocation score era. J Surg Res 2019; 234:84–95.
Ranganath NK, Malas J, Phillips KG, et al. Single and double lung transplantation have equivalent survival for idiopathic pulmonary fibrosis. Ann Thorac Surg 2020; 109:211–217.
Anderson MR, Tabah A, RoyChoudhury A, Lederer DJ. Procedure preference and intention-to-treat outcomes after listing for lung transplantation among U.S. adults: a cohort study. Ann Am Thorac Soc 2019; 16:231–239.
Egan TM, Kotloff RM. Pro/con debate: lung allocation should be based on medical urgency and transplant survival and not on waiting time. Chest 2005; 128:407–415.
Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report. J Hear Lung Transplant 2005; 24:956–967.
Merlo CA, Weiss ES, Orens JB, et al. Impact of U.S. lung allocation score on survival after lung transplantation. J Hear Lung Transplant 2009; 28:769–775.
De Oliveira NC, Osaki S, Maloney J, et al. Lung transplant for interstitial lung disease: outcomes before and after implementation of the united network for organ sharing lung allocation scoring system. Eur J Cardiothoracic Surg 2012; 41:680–685.
Schuba B, Scheklinski M, Von Dossow V, et al. Five-year experience using the Lung Allocation Score: the Munich Lung Transplant Group. Eur J Cardiothoracic Surg 2018; 54:328–333.
Kern RM, Singer JP, Koth L, et al. Lung transplantation for hypersensitivity pneumonitis. Chest 2015; 147:1558–1565.
Khawar MU, Yazdani D, Zhu Z, et al. Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis. J Hear Lung Transplant 2019; 38:949–955.
Pradère P, Tudorache I, Magnusson J, et al. Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study. J Hear Lung Transplant 2018; 37:903–911.
Lo WK, Goldberg HJ, Wee J, et al. Both pre-transplant and early post-transplant antireflux surgery prevent development of early allograft injury after lung transplantation. J Gastrointest Surg 2016; 20:111–118.
Taimeh Z, Hertz MI, Shumway S, Pritzker M. Lung transplantation for pulmonary sarcoidosis: twenty-five years of experience in the USA. Thorax 2016; 71:378–379.
Yazdani A, Singer LG, Strand V, et al. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Hear Lung Transplant 2014; 33:514–520.
Courtwright AM, El-Chemaly S, Dellaripa PF, Goldberg HJ. Survival and outcomes after lung transplantation for nonscleroderma connective tissue-related interstitial lung disease. J Hear Lung Transplant 2017; 36:763–769.
Leclair V, Labirua-iturburu AN, Lundberg IE, Antibodies AD. Successful Lung Transplantation in a case of rapidly progressive interstitial lung disease associated with antimelanoma differentiation-associated gene 5 antibodies. J Rheumatol 2018; 45:581–583.
Newton CA, Kozlitina J, Lines JR, et al. Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival. J Hear Lung Transplant 2017; 36:845–853.
Tokman S, Singer JP, Devine MS, et al. Clinical outcomes of lung transplant recipients with telomerase mutations. J Hear Lung Transplant 2015; 34:1318–1324.
Silhan LL, Shah PD, Chambers DC, et al. Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. Eur Respir J 2014; 44:178–187.
Popescu I, Mannem H, Winters SA, et al. Impaired cytomegalovirus immunity in idiopathic pulmonary fibrosis lung transplant recipients with short telomeres. Am J Respir Crit Care Med 2019; 199:362–376.
Swaminathan AC, Neely ML, Frankel CW, et al. Lung transplant outcomes in patients with pulmonary fibrosis with telomere-related gene variants. Chest 2019; 156:477–485.
Newton CA, Zhang D, Oldham JM, et al. Telomere length and use of immunosuppressive medications in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2019; 200:336–347.
Faust HE, Golden JA, Rajalingam R, et al. Short lung transplant donor telomere length is associated with decreased CLAD-free survival. Thorax 2017; 72:1052–1054.
Banga A, Sahoo D, Lane CR, et al. Disease recurrence and acute cellular rejection episodes during the first year after lung transplantation among patients with sarcoidosis. Transplantation 2015; 99:1940–1945.
Yserbyt J, Wuyts WA, Verleden SE, et al. Solid organ transplantation in sarcoidosis. Semin Respir Crit Care Med 2017; 38:538–545.
Kurosaki T, Otani S, Miyoshi K, et al. Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation: long-term follow-up of a Japanese center. Clin Respir J 2020; 14:116–123.
Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin 2019; 35:2015–2024.
De Sadeleer LJ, Hermans F, De Dycker E, et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J Clin Med 2019; 8:1–11.
Nunes H, Schubel K, Piver D, et al. Nonspecific interstitial pneumonia: survival is influenced by the underlying cause. Eur Respir J 2015; 45:746–755.
Bode H, Verleden SE, Wuyts WA, et al. Outcome of lung transplantation in nonidiopathic pulmonary fibrosis interstitial lung disease. Clin Transplant 2019; 33:e13661[Epub ahead of print].
Tuyls S, Verleden SE, Wuyts WA, et al. Determinants of survival in lung transplantation patients with idiopathic pulmonary fibrosis: a retrospective cohort study. Transpl Int 2019; 32:399–409.
Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45:1434–1445.
Ruwanpura SM, Thomas BJ, Bardin PG. Pirfenidone: molecular mechanisms and potential clinical applications in lung disease. Am J Respir Cell Mol Biol 2020; 62:413–422. doi:10. 1165/rcmb.2019-2328.
doi: 10.
Vos R, Wuyts WA, Gheysens O, et al. Pirfenidone in restrictive allograft syndrome after lung transplantation: a case series. Am J Transplant 2018; 18:3045–3059.
Leuschner G, Stocker F, Veit T, et al. Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous antifibrotic therapy. J Hear Lung Transplant 2018; 37:268–274.
Lambers C, Boehm PM, Lee S, et al. Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis. Eur Respir J 2018; 51:1800503.
Clausen ES, Frankel C, Palmer SM, et al. Pretransplant weight loss and clinical outcomes after lung transplantation. J Hear Lung Transplant 2018; 37:1443–1447.
Jouneau S, Kerjouan M, Rousseau C, et al. What are the best indicators to assess malnutrition in idiopathic pulmonary fibrosis patients? A cross-sectional study in a referral center. Nutrition 2019; 62:115–121.
Kim CY, Kim SY, Song JH, et al. Usefulness of the preoperative prognostic nutritional index score as a predictor of the outcomes of lung transplantation: a single-institution experience. Clin Nutr 2019; 38:2423–2429.
Ryerson CJ, Arean PA, Berkeley J, et al. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology 2012; 17:525–532.
Bleisch B, Macé SM, Richard K, et al. Health-related quality of life and stress-related posttransplant trajectories of lung transplant recipients: a three-year follow-up of the Swiss Transplant Cohort Study. Swiss Med Wkly 2019; 149:w20019.
Smith PJ, Blumenthal JA, Trulock EP, et al. Psychosocial predictors of mortality following lung transplantation. Am J Transplant 2016; 16:271–277.
Guler SA, Kwan JM, Leung JM, et al. Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes. Eur Respir J 2020; 55:1900647.
Florian J, Watte G, Teixeira PJ, et al. Pulmonary rehabilitation improves survival in patients with idiopathic pulmonary fibrosis undergoing lung transplantation. Sci Rep 2019; 9:1–6.